Navigation Links
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Date:11/5/2009

, completion of all AGW trial activities in accordance with the trial design and schedule. Important risk factors and uncertainties that could cause actual results to differ materially from these forward-looking statements and information include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse impact on the Company and its ability to continue, or if not obtained in a timely manner, may result in the Company's having to discontinue or delay one or more of its product development programs, including the AGW trial; uncertainty whether Topical Interferon Alpha-2b will be successfully developed and commercialized as a drug for the treatment of AGW or at all; uncertainty whether any of the timelines mentioned in this press release will be achieved; Helix's dependence on its third party service providers, including without limitation, contract research organizations, contract manufacturing organizations, clinical trial consultants, collaborative research consultants, regulatory affairs advisors, and others, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; the risk that the AGW trial may fail to meet expectations and that further development of the drug candidate may be discontinued for the AGW indication; the need for additional clinical trials, if the AGW trial does meet expectations, to continue the development of the drug candidate, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, including the possibility that further challenges may arise in connection with the scale-up manufacturing of Topical Interferon Alpha-2b; the risk of obtaining negative findings or factors that may become apparent during the course of research or development, including during the course of the AGW trial, w
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioPharma Corp. Announces Fiscal 2009 Results
2. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
3. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
6. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cardium Therapeutics,(Amex: CXM ) and its ... findings from a preclinical study, demonstrating a ... (cooling) for the potential,treatment of acute myocardial ... BioMed Central (BMC) Cardiovascular Disorders (2008, 8:7, ...
... - New Approach to Targeting the Tumor ... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... the extracellular matrix, today,announced new pre-clinical findings ... the American Association for Cancer Research (AACR) ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 2Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 3Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 4
(Date:7/10/2014)... According to a new market research ... Airborne, Naval), Application (Software Defined Radios, SATCOM, Encryption, ... America, Asia-Pacific, Europe, the Middle East & ROW) ... the market is estimated to be $30.15 billion ... CAGR of 5.56% to reach $39.52 billion by ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
(Date:7/10/2014)... not nurture, may play the bigger role in the ... "As is the case in humans, genes matter ... William Hopkins of the Yerkes National Primate Research Center ... journal Current Biology . The findings might ... humans, Hopkins, team said. According to the researchers, ...
(Date:7/10/2014)... who are sensitive to light or noise after a ... as anxiety and depression, a new study says. ... teens experience after concussion may help in planning for ... to return to play and what accommodations are needed ... and Dong Han, of the University of Kentucky in ...
Breaking Medicine News(10 mins):Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... , , IRVING, Texas, ... (OTC Bulletin Board: RBCL), a provider of proprietary nutritional supplements and ... the ClearPay System, a compensation plan that rewards the company,s independent ... The ClearPay System is the ...
... , , , ... with painful conditions, September is a time for their true ... communication, National Pain Awareness Month allows people with painful conditions ... fight their pain. , , Fibromyalgia has ...
... of infections on campus already increasing rapidly; could ... , TUESDAY, Sept. 8 (HealthDay News) -- Erica Goldfine, ... to school this semester to find a new item ... cheating: emergency preparedness procedures for the H1N1 swine flu. ...
... , CLAREMONT, Calif., Sept. 8 ... that personalized medicine will have on life science companies, physicians, patients, ... "Personalized medicine will change how medicine is delivered," said Diana Bartlett, ... longer one size fits all. Your therapy may be different from ...
... Ala., Sept. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ... two upcoming investor conferences. , , ... to present a corporate summary at the Rodman & Renshaw Annual ... Eastern Time. The conference will be held September 9-11, 2009 in ...
... , , JACKSONVILLE, Fla., Sept. 8 ... to getting the job done. Yet, new research reveals that as they ... to perform everyday activities at home and on the job. , ... are concerned that their vision is getting worse as they age, and ...
Cached Medicine News:Health News:RBC Life Sciences Unveils the ClearPay System - the Industry's First Balancing Compensation Plan That Pays Quickly and Abundantly 2Health News:RBC Life Sciences Unveils the ClearPay System - the Industry's First Balancing Compensation Plan That Pays Quickly and Abundantly 3Health News:Know Fibro Initiative Commemorates National Pain Awareness Month 2Health News:Know Fibro Initiative Commemorates National Pain Awareness Month 3Health News:Colleges Move to Limit Swine Flu's Spread 2Health News:Colleges Move to Limit Swine Flu's Spread 3Health News:Colleges Move to Limit Swine Flu's Spread 4Health News:KGI to Host Public Discussion on Personalized Medicine 2Health News:BioCryst Executives to Present at Two Investor Conferences 2Health News:Working Moms' Vision Not 'Near' Perfect 2Health News:Working Moms' Vision Not 'Near' Perfect 3
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: